



**Figure S1.** Baseline and Post-Treatment Exosome Shedding. (A) CD9<sup>+</sup> and (B) CD63<sup>+</sup> purified exosomes from patients with HCC at baseline and post-treatment. Abbreviations: Exosomes (EXs).

**Table S1.** Exosome shedding by first cycle response to LDT in HCC.

EXs Shedding by Response	Baseline	Post-LDT	<i>P</i> value
<b>CD9<sup>+</sup> EXs, median (IQR)</b>			
ORR	8.8×10 <sup>6</sup> (4.0×10 <sup>6</sup> – 25.7×10 <sup>6</sup> )	10.8×10 <sup>6</sup> (5.4×10 <sup>6</sup> – 22.0×10 <sup>6</sup> )	0.461
Non-ORR	5.0×10 <sup>6</sup> (3.1×10 <sup>6</sup> – 9.9×10 <sup>6</sup> )	4.1×10 <sup>6</sup> (2.8×10 <sup>6</sup> – 7.5×10 <sup>6</sup> )	0.534
<b>CD63<sup>+</sup> EXs, median (IQR)</b>			
ORR	0.55×10 <sup>6</sup> (0.3×10 <sup>6</sup> – 1.0×10 <sup>6</sup> )	0.7×10 <sup>6</sup> (0.4×10 <sup>6</sup> – 0.9×10 <sup>6</sup> )	0.888
Non-ORR	0.55×10 <sup>6</sup> (0.3×10 <sup>6</sup> – 1.6×10 <sup>6</sup> )	0.8×10 <sup>6</sup> (0.36×10 <sup>6</sup> – 1.1×10 <sup>6</sup> )	0.759
<b>CD9<sup>+</sup> CD63<sup>+</sup> EXs, median (IQR)</b>			
ORR	0.09×10 <sup>6</sup> (0.03×10 <sup>6</sup> – 0.2×10 <sup>6</sup> )	0.1×10 <sup>6</sup> (0.04×10 <sup>6</sup> – 0.4×10 <sup>6</sup> )	0.354
Non-ORR	0.08×10 <sup>6</sup> (0.02×10 <sup>6</sup> – 0.5×10 <sup>6</sup> )	0.08×10 <sup>6</sup> (0.05×10 <sup>6</sup> – 0.5×10 <sup>6</sup> )	0.471

Abbreviations: Interquartile range (IQR); Hepatocellular carcinoma (HCC); Liver-directed therapy (LDT); Exosomes (EXs); Objective response rate (ORR).